Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
about
Therapeutic cancer vaccines: past, present, and futureTargeting the Bcl-2 family for cancer therapyRecent advances in therapeutic cancer vaccinesVaccines against human carcinomas: strategies to improve antitumor immune responses.Potential utility of the pan-Bcl-2 inhibitor GX15-070 (obatoclax) in cancer immunotherapy.Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapyDual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyAbscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation.Therapeutic cancer vaccines: current status and moving forward.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsDistinct effects of saracatinib on memory CD8+ T cell differentiation.Poxviral vectors for cancer immunotherapyTherapeutic cancer vaccines: the latest advancement in targeted therapy.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise.Therapeutic cancer vaccines: a long and winding road to success.BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
P2860
Q26863283-D4BD6ACC-6D61-4608-A22B-27CF642CFF73Q26866936-BA4EC0B5-58E8-4B8D-A8A1-8BF4689B311FQ27025266-0F9D79A6-B29F-439D-985C-1F5D87FA673AQ33734281-9ECDE2B0-3DF6-4D2E-8C27-B27B9A77A1BEQ33940448-D38D4E7D-EAE7-4F64-AAB2-806EF50E10FEQ34004454-009F5904-0AE2-4527-B13A-1BA8D61CC320Q34537725-815DC1CE-1218-47FB-89D5-0607D949C0D9Q35597086-A0F1846B-7827-4133-9F7A-BB043F9A2E90Q35752201-592689C5-ADCD-43AA-AF5F-9F995518CD38Q35894347-C7623C9C-2908-4E3B-8AA8-2908A54C668DQ35975387-B7C06416-DA3D-4B58-8C90-C9F1CBE55357Q36043797-D8C8EBBD-7CBE-44BA-9560-8A2129D90705Q36350388-7802C777-EA3D-454A-9E49-4A477DDB5E8AQ36695629-6C27EC18-7324-4A0F-8A2A-41AE4F213232Q36708792-D4015813-474B-447A-A533-9BA561AE8307Q37521403-28514D27-668A-4854-BE2A-11D34EB4F063Q38113267-6D34FFB4-869E-4DE0-A913-1A2A6331EAB4Q38162261-D4E5D99D-2918-4835-852E-CFAD04CF426EQ58763373-54E53997-438F-4664-97F2-75490CB520F1
P2860
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@ast
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@en
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@nl
type
label
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@ast
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@en
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@nl
prefLabel
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@ast
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@en
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@nl
P2093
P2860
P356
P1476
Effect of a small molecule BCL ...... se with a recombinant vaccine.
@en
P2093
Helen Sabzevari
Jack P Higgins
James W Hodge
Jeffrey Schlom
Maria Giovanna Di Bari
Shinji Takai
P2860
P304
P356
10.1002/IJC.25177
P577
2010-10-01T00:00:00Z